Marketed under the name, Bio2Source, Oncobiologics and Stelis Biopharma will offer development stage biotech companies access to a suite of CDMO services. Oncobiologics will utilize its proprietary BioSymphony™ platform to offer mammalian cell process development and bulk drug manufacturing, while Stelis will offer microbial development and manufacturing capabilities as well as fill-finish services, including drug formulation development and lyophilization for biological products.

Joe Thomas, chief executive officer of Stelis Biopharma and member of the Oncobiologics Board of Directors, stated, “We are excited to launch this collaboration at BIO 2018.  We believe this CDMO concept offers development stage biotech companies an exciting ‘DNA to clinic’ option for preparing their biologic products for clinical trials and commercial launch.  They can access technical excellence, rapid development and attractive economics not found with other CDMO business models.”

“We are pleased to leverage our BioSymphony platform capacity with development stage partners.  Our CDMO offering has already generated great interest and we look forward to meeting with additional prospective partners at BIO to further educate them on our innovative services model,” commented Pankaj Mohan, Ph.D., chairman and chief executive officer of Oncobiologics.

The Bio2Source initiative is facilitated by GMS Tenshi, a significant strategic investor both in Stelis Biopharma and Oncobiologics Inc. GMS Tenshi, based in Singapore, is a joint-venture between Tenshi Life Sciences Private Limited, an India based life sciences company and GMS Holdings, a Jordan based group with diversified assets across the pharmaceutical and biopharmaceutical space.